» Articles » PMID: 17631134

Progressive Fibrosis in Nonalcoholic Steatohepatitis: Association with Altered Regeneration and a Ductular Reaction

Abstract

Background & Aims: Portal fibrosis and linkage is a key feature of progressive disease in nonalcoholic steatohepatitis (NASH), but not simple steatosis. It is underappreciated and poorly understood. Fatty liver has impaired regeneration that induces a secondary replicative pathway using bipotential, periportal, hepatic progenitor cells (HPCs). We propose that activation of this pathway, with increased cell injury in NASH, also induces a periportal ductular reaction (DR) that could produce a profibrogenic stimulus.

Methods: Biopsy specimens from 107 patients with nonalcoholic fatty liver disease and 11 controls were immunostained with cytokeratin-7 to quantify the DR and HPCs, and with p21 to assess hepatocyte replicative arrest. These results were correlated with clinicopathologic variables.

Results: Patients with nonalcoholic fatty liver disease had expansion of HPCs, with a strong association between HPCs and the DR (r(s) = 0.582, P < .0001). In those with NASH (n = 69) there was an increased DR compared with simple steatosis, which correlated with the stage of fibrosis (r(s) = 0.510, P < .0001). The DR increased with the grade of NASH activity (r(s) = 0.478, P < .0001), grade of portal inflammation (r(s) = 0.445, P < .0001), and extent of hepatocyte replicative arrest (r(s) = 0.446, P < .0001). Replicative arrest was in turn associated with insulin resistance (r(s) = 0.450, P < .0001) and NASH activity (r(s) = 0.452, P < .0001). By multivariate analysis, the extent of DR (odds ratio [OR] = 17.9, P = .016), hepatocyte ballooning (OR = 8.1, P < .0001), and portal inflammation (OR = 3.3, P = .005) were associated independently with fibrosis.

Conclusions: These findings suggest that an altered replication pathway in active NASH promotes a periportal DR, which in turn may provoke progressive periportal fibrogenesis.

Citing Articles

MetALD: Clinical aspects, pathophysiology and treatment.

Gratacos-Gines J, Arino S, Sancho-Bru P, Bataller R, Pose E JHEP Rep. 2025; 7(2):101250.

PMID: 39897615 PMC: 11782861. DOI: 10.1016/j.jhepr.2024.101250.


Evaluation of autoimmune phenomena in patients with nonalcoholic fatty liver disease on the basis of liver pathology.

Zhu Y, Zhang Y, Rao Y, Jiang Y, Liu Y, Li J World J Hepatol. 2025; 16(12):1407-1416.

PMID: 39744192 PMC: 11686539. DOI: 10.4254/wjh.v16.i12.1407.


Alleviating batch effects in cell type deconvolution with SCCAF-D.

Feng S, Huang L, Pournara A, Huang Z, Yang X, Zhang Y Nat Commun. 2024; 15(1):10867.

PMID: 39738054 PMC: 11686230. DOI: 10.1038/s41467-024-55213-x.


Osteopontin Promotes Cholangiocyte Secretion of Chemokines to Support Macrophage Recruitment and Fibrosis in MASH.

Coombes J, Manka P, Swiderska-Syn M, Vannan D, Riva A, Claridge L Liver Int. 2024; 45(4):e16131.

PMID: 39422353 PMC: 11893260. DOI: 10.1111/liv.16131.


Portal Fibrosis and the Ductular Reaction: Pathophysiological Role in the Progression of Liver Disease and Translational Opportunities.

Gupta V, Sehrawat T, Pinzani M, Strazzabosco M Gastroenterology. 2024; .

PMID: 39251168 PMC: 11885590. DOI: 10.1053/j.gastro.2024.07.044.